Reimagining the future of Huntington’s disease

SOPHIA Huntington’s Disease Community Advocate

Home hero advocate sophia 2

Press Releases

Nov 4, 2026
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
Nov 2, 2026
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
Oct 28, 2026
uniQure to Announce Third Quarter 2026 Financial Results

See All